ClinicalTrials.gg
Enrolling by invitationNCT07620574Updated Oct 28, 2026

Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study

A Phase 3 interventional study of Cabozantinib and Zanzalintinib in Cancer, Renal Cell Carcinoma (RCC) and Pancreatic Neuroendocrine Tumors (pNET), sponsored by Exelixis. Enrolling by invitation at 4 sites in United States. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Exelixis · Phase 3, Interventional, and Treatment

Updated Oct 28, 20262 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
5,000
Allocation
Not applicable
Sex
All
01

Study summary

The primary objective of this long-term extension study is to allow continued access to study treatment for eligible participants who are deriving clinical benefit in an Exelixis-sponsored study who do not have access to treatment locally.

02

Conditions studied

  • Cancer
  • Renal Cell Carcinoma (RCC)
  • Pancreatic Neuroendocrine Tumors (pNET)
  • Extra-Pancreatic NET (epNET)
  • Hepatocellular Carcinoma (HCC)
  • Differentiated Thyroid Cancer (DTC)
  • Non-Clear Cell Renal Cell Carcinoma (nccRCC)
  • Colorectal Cancer
  • Prostate Cancer

Keywords

  • Renal Cell Carcinoma (RCC)
  • Pancreatic Neuroendocrine Tumors (pNET)
  • Extra-Pancreatic NET (epNET)
  • Hepatocellular Carcinoma (HCC)
  • Differentiated Thyroid Cancer (DTC)
  • Non-Clear Cell Renal Cell Carcinoma (nccRCC)
  • Colorectal Cancer
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.

This study's planned enrollment of 5,000 is above the median of 60 across 7,706 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Exelixis is the lead sponsor of 57 studies on the registry; 11 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Eligible to continue receiving the study treatment in the parent study (that is, has not met parent study discontinuation/withdrawal criteria).
  • Continuing to derive clinical benefit from the study treatment at the time of transition from the parent study as assessed by the investigator.
  • Able to comply with the long-term extension study protocol as determined by the investigator.
  • Able to receive the first dose of study treatment in this extension study within the specified treatment interruption window allowed by the parent study.

Key Exclusion Criteria:

  • Meet any of the study treatment discontinuation criteria specified in the parent study at the time of enrollment in this extension study.
  • Study treatment is commercially marketed in the participant's country for the participant-specific disease and is accessible to the participant.
  • Treatment with any anticancer treatment (other than treatment permitted in the parent study) during the time between last treatment in the parent study and the first dose of study treatment in this long-term extension study.
  • Permanent discontinuation of all study treatment(s) for any reason during the parent study or during the time between last treatment in the parent study and the first dose of study treatment in this long-term extension study (if applicable).
  • Concurrent participation in any therapeutic clinical trial (other than the parent study).

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5,000 participants (estimated)

Study arms

  • Experimental
    Cabozantinib/Zanzalintinib

    Depending on the study treatment received in the parent study, participants may receive cabozantinib alone or in combination with other agents; zanzalintinib alone or in combination with other agents, or comparator.

    Drug: Cabozantinib · Drug: Zanzalintinib · Drug: Atezolizumab · Drug: Nivolumab · Drug: Abiraterone · Drug: Prednisone · Drug: Enzalutamide

Interventions

  • Administered as specified in the parent study.

    Also known as: XL184, Cabometyx

  • Administered as specified in the parent study.

    Also known as: XL092

  • Administered as specified in the parent study.

  • Administered as specified in the parent study.

  • Administered as specified in the parent study.

  • Administered as specified in the parent study.

  • Administered as specified in the parent study.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    Time frame: Up to 4 years (until the event resolves, returns to baseline, stabilizes, a new anticancer therapy is initiated, or the participant is lost to follow-up or withdraws consent, whichever occurs first)

07

Study locations

4 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for May 2030, 46 months after the start.

Of 119 industry-sponsored phase 3 interventional studies under Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 72. This study's planned 46 months is close to that.

Counting every sponsor, half of 202 studies reached it within 50 months; a quarter within 33 and three quarters within 84.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2026
First posted
Jun 2, 2026
StartActual
Jul 30, 2026
Primary completionEst.
May 31, 2030
CompletionEst.
May 31, 2030
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (2 United States)
  • The West Clinic · Memphis, United States
  • The University of Texas MD Anderson Cancer Center · Houston, United States
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    2 sites added
    Show 2 added (2 United States)
    • The West Clinic · Memphis, United States
    • The University of Texas MD Anderson Cancer Center · Houston, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07620574
Lead sponsor
Exelixis
Responsible party
Sponsor
First posted
Jun 2, 2026
Start date
Jul 30, 2026
Primary completion
May 31, 2030 (estimated)
Completion
May 31, 2030 (estimated)
Last update
Oct 28, 2026

Study contacts

Medical Director
study director · Exelixis

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cabozantinib · Zanzalintinib

Start the discussion